Logos Global Management LP Has $8.34 Million Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Logos Global Management LP increased its holdings in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 27.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,800,000 shares of the company’s stock after purchasing an additional 600,000 shares during the period. Logos Global Management LP’s holdings in Trevi Therapeutics were worth $8,344,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in TRVI. Ally Bridge Group NY LLC purchased a new position in shares of Trevi Therapeutics during the second quarter valued at approximately $4,395,000. Hsbc Holdings PLC bought a new stake in Trevi Therapeutics during the second quarter worth $61,000. Dimensional Fund Advisors LP lifted its holdings in Trevi Therapeutics by 217.6% during the second quarter. Dimensional Fund Advisors LP now owns 72,210 shares of the company’s stock worth $215,000 after acquiring an additional 49,475 shares during the period. American Century Companies Inc. raised its stake in shares of Trevi Therapeutics by 17.1% in the second quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock valued at $161,000 after buying an additional 7,902 shares during the period. Finally, Rhumbline Advisers raised its stake in shares of Trevi Therapeutics by 44.8% in the second quarter. Rhumbline Advisers now owns 75,218 shares of the company’s stock valued at $224,000 after buying an additional 23,263 shares during the period. Institutional investors and hedge funds own 95.76% of the company’s stock.

Insider Buying and Selling at Trevi Therapeutics

In related news, insider Thomas Sciascia sold 18,660 shares of the stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $2.76, for a total value of $51,501.60. Following the completion of the sale, the insider now owns 220,315 shares in the company, valued at $608,069.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CEO Jennifer L. Good sold 10,981 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total value of $33,162.62. Following the completion of the transaction, the chief executive officer now owns 213,313 shares of the company’s stock, valued at approximately $644,205.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Thomas Sciascia sold 18,660 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $2.76, for a total transaction of $51,501.60. Following the sale, the insider now directly owns 220,315 shares in the company, valued at $608,069.40. The disclosure for this sale can be found here. Insiders sold 40,355 shares of company stock worth $116,663 over the last ninety days. Company insiders own 24.37% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on TRVI shares. Raymond James assumed coverage on Trevi Therapeutics in a research report on Friday, August 30th. They issued an “outperform” rating and a $9.00 price target for the company. EF Hutton Acquisition Co. I raised Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, August 19th. Leerink Partners assumed coverage on Trevi Therapeutics in a research note on Monday, September 9th. They set an “outperform” rating and a $7.00 target price on the stock. Rodman & Renshaw assumed coverage on Trevi Therapeutics in a research note on Thursday, June 13th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Leerink Partnrs raised Trevi Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $7.67.

Trevi Therapeutics Stock Down 4.1 %

Shares of NASDAQ TRVI opened at $3.30 on Tuesday. Trevi Therapeutics, Inc. has a 52-week low of $0.97 and a 52-week high of $4.00. The business has a 50-day moving average price of $3.00 and a 200 day moving average price of $2.91. The stock has a market cap of $232.44 million, a PE ratio of -9.71 and a beta of 0.96.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same quarter in the prior year, the firm earned ($0.07) earnings per share. Sell-side analysts anticipate that Trevi Therapeutics, Inc. will post -0.47 earnings per share for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.